Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID CHECK: Acalabrutinib + Pembrolizumab in Urothelial Carcinoma
NCT02351739Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Apr 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acalabrutinib in urothelial carcinoma (UC) (2 arms), sponsored by Acerta Pharma. Primary endpoint: Overall Response Rate. Started Apr 2015; status: completed.
02
Drugs
acalabrutinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02351739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351739.